Dicerna Pharmaceuticals - Stock Price History | DRNA

Historical daily share price chart and data for Dicerna Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Dicerna Pharmaceuticals as of September 27, 2021 is 20.85.
  • The all-time high Dicerna Pharmaceuticals stock closing price was 46.00 on January 30, 2014.
  • The Dicerna Pharmaceuticals 52-week high stock price is 40.14, which is 92.5% above the current share price.
  • The Dicerna Pharmaceuticals 52-week low stock price is 17.76, which is 14.8% below the current share price.
  • The average Dicerna Pharmaceuticals stock price for the last 52 weeks is 26.49.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Dicerna Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 20.9364 22.0600 26.6200 13.3700 22.0300 0.00%
2019 14.9216 11.7700 26.9150 9.7400 22.0300 106.08%
2018 12.7777 9.3600 17.6900 8.4200 10.6900 18.38%
2017 4.2481 2.9700 9.8400 2.4500 9.0300 213.54%
2016 4.3493 11.3900 11.3900 2.7000 2.8800 -75.74%
2015 15.8670 17.5900 26.9400 8.0200 11.8700 -27.93%
2014 18.9106 46.0000 46.0000 8.1400 16.4700 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.621B $0.164B
Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29